Risk-stratified Therapy for Acute Myeloid Leukemia in Down Syndrome: A COG Groupwide Phase III Study

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Acute Myeloid Leukemia In Down Syndrome
  • Age: Between 90 - 3 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Patients must have constitutional trisomy 21 (Down syndrome) or trisomy 21 mosaicism (by karyotype or FISH) and have been diagnosed with Acute Myeloid Leukemia (AML) or Myelodysplastic syndrome (MDS). 2) Patients has one of the following: patient has previously untreated de novo AML and meets the criteria for AML with = 20% bone marrow blasts, patient has cytopenias and/or bone marrow blasts but does not meet the criteria for the diagnosis of AML and meets the criteria for a diagnosis of MDS, patient has a history of Transient Myeloproliferative Disorder (TMD).

You may not be eligible for this study if the following are true:

  • 1) Children who have previously received chemotherapy, radiation therapy or any anti-leukemic therapy are not eligible for this study. 2) Patients with promyelocytic leukemia (FAB M3). 3) For prior therapy, Patients = 30 days from the last dose of cytarabine used for treatment of TMD.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.